Liquidia (LQDA) CEO Roger Jeffs Sells $933K of Stock

Roger Jeffs, the Chief Executive Officer of Liquidia Corporation (LQDA), sold 32,744 shares at a price of $28.48 each on October 12, 2026. This sale was valued at approximately $932,549. Jeffs' transaction was part of a planned sale, which is common for executives managing their stock holdings.

Inside Roger Jeffs' Trade

Jeffs sold his shares at a price of $28.48, which was below the stock's recent trading price of $33.77 as of October 16, 2026. This move follows a recent pattern of insider selling at Liquidia, as other executives also sold shares on the same day. For instance, Sarah Krepp, the Chief Human Resource Officer, sold 5,245 shares, while Chief Operating Officer Michael Kaseta sold 18,938 shares.

Other Institutional Activity in Liquidia Corporation

Several institutional investors have been active in Liquidia Corporation recently. Blackrock Inc. increased its holdings by 529,932 shares, bringing its total to 10,788,586 shares valued at approximately $370.6 million. Vanguard Capital Management LLC added 212,206 shares, resulting in a total of 3,139,183 shares worth about $107.8 million. Meanwhile, Farallon Capital Management LLC reduced its stake by 290,837 shares, holding now 8,365,038 shares valued at around $287.3 million.

Liquidia Corporation Stock Down 2.9%

As of October 16, 2026, Liquidia's stock was trading around $33.77, which is significantly below its 50-day moving average of $61.62 and its 200-day average of $53.93. The stock is also about 63.9% lower than its 52-week high of $93.61, indicating a challenging market environment for the company.

Recent Earnings

Liquidia Corporation reported trailing twelve-month revenue of $450.9 million and an earnings per share (EPS) of $1.39. The company has shown impressive revenue growth year-over-year at 1,842.7%. The next earnings report is scheduled for November 3, 2026.

Insider Buying and Selling at Liquidia Corporation

On the same day as Jeffs' sale, other insiders also sold shares. Krepp sold 5,245 shares for a total value of about $149,377.6, while Dana Boyle, an officer, sold 5,892 shares valued at approximately $167,804. Sanjeev Khindri, another officer, sold 1,101 shares worth about $31,356. All these transactions were executed at the same price of $28.48 per share.

Analysts Set New Price Targets

On October 1, 2026, Raymond James downgraded Liquidia's stock to an "Outperform" rating with a new target of $53, down from $106. BTIG also downgraded the stock to "Neutral." Needham maintained a "Buy" rating with a target of $72, while Wells Fargo downgraded to "Equal-Weight" with a target of $30. The consensus rating from analysts remains a "Buy" with a mean price target of $54.38.

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company based in Morrisville, North Carolina. It focuses on developing and commercializing treatments for rare cardiopulmonary diseases. Its lead product is YUTREPIA, an inhaled formulation for treating pulmonary arterial hypertension and related conditions. The recent insider sales and analyst downgrades reflect the ongoing adjustments in market sentiment regarding the company's future prospects.

Bottom Line

Investors should watch for Liquidia's upcoming earnings report on November 3, 2026, as it may provide further insights into the company's performance. Additionally, the recent insider selling patterns may suggest shifts in executive confidence regarding future stock performance.